Pharmaceutical company Dr. Reddy’s Laboratories on Monday announced the commercial launch of anti-Covid19 drug 2-deoxy-D-glucose (2-DG), developed in collaboration with Defence Research and Development Organisation (DRDO).
Dr. Reddy’s will supply the anti-Covid19 drug to major government as well as private hospitals across India.
In the initial weeks, the company will make the drug available in hospitals across metros and Tier 1 cities, and subsequently expand coverage to the rest of India.
“2-DG manufactured by Dr Reddy’s has a purity of 99.5% and is being sold commercially under the brand name 2DGTM,” the company said in a statement.
The maximum retail price (MRP) of each sachet has been fixed at Rs. 990, with a subsidized rate offered to government institutions.
The oral drug can be administered only upon prescription and under the supervision of a qualified physician to hospitalised moderate to severe COVID19 patients as an adjunct therapy to the existing standard of care.
Emergency use approval for anti-COVID19 therapeutic application of the drug was granted on May 1, 2021.
Dr. G. Satheesh Reddy, Secretary to the Department of Defence (R&D) and chairman, DRDO said, “We are pleased to have worked closely with our long-term industry partner Dr. Reddy’s Laboratories, Hyderabad, for testing 2-DG as therapeutic application in treatment of COVID-19 patients.”
Also read: Anti-COVID-19 drug 2-DG released
“DRDO has been contributing in fight against COVID-19 pandemic with its spin off technologies,” Reddy added.
Satish Reddy, chairman of Dr. Reddy’s said, “2-DG is yet another addition to our COVID19 portfolio that already covers the full spectrum of mild to moderate and severe conditions and includes a vaccine.”
“We are extremely pleased to have partnered with DRDO in our collective fight against the COVID-19 pandemic,” he added.
2-DG was developed by theInstitute of Nuclear Medicine & Allied Sciences(INMAS), a laboratory of the DRDO, in collaboration with Dr. Reddy’s.